GO
Loading...

Drug Retail

More

  • Ethics of 'right to try' laws     Tuesday, 6 May 2014 | 2:35 PM ET

    Lawmakers in four states are considering changing the rules to allow terminally ill people access to experimental drugs before they have FDA approval. Kenneth Goodman, University of Miami, thinks this would be a bad bet for patients. Miles Nadal, MDC Partners Chairman & CEO, weighs in.

  • Pharma deal of the day     Tuesday, 6 May 2014 | 12:27 PM ET

    CNBC's Meg Tirrell spoke with Merck Chairman & CEO Ken Frazier about the company's decision to sell its over the counter health care products to Bayer.

  • *Apple shares in spotlight after closing above $600. *Shares of Office Depot Inc jumped 10 percent in premarket trading even as it reported a quarterly loss and said it would shut at least 400 stores in the United States, hurt by competition from e-retailers, mass market chains and drugstores.

  • *Apple shares in spotlight after closing above $600. *Shares of Office Depot Inc jumped 8 percent in premarket trading even as it reported a quarterly loss and said it would shut at least 400 stores in the United States, hurt by competition from e-retailers, mass market chains and drugstores.

  • Office Depot to close 400 U.S. stores, posts loss Tuesday, 6 May 2014 | 7:13 AM ET

    May 6- Office Depot Inc said it would close at least 400 stores in the United States as shoppers shift their office supply purchases to e-retailers, mass market chains and drugstores. Office Depot, which also reported a quarterly net loss, said it expects to close 150 stores this year.

  • May 2- CVS Caremark Corp reported a weaker-than-expected quarterly profit on Friday on a sharp drop in sales of general merchandise, which the drugstore chain blamed on a harsh winter, milder flu season and aggressive competition.

  • Activist Jana sees opportunities in this stock Tuesday, 22 Apr 2014 | 4:07 PM ET
    Barry Rosenstein, founder and managing partner of Jana Partners

    Walgreen's pending acquisition of Alliance Boots can mean lower taxes and a better company, according to activist investor Barry Rosenstein.

  • Eli Lilly Chairman & CEO John Lechleiter discusses his business' expansion of its animal health unit with the acquisition of Novartis' animal health business.

  • Novartis acquisition adds 'tremendous value'     Tuesday, 22 Apr 2014 | 6:45 AM ET

    GlaxoSmithKline CEO Sir Andrew Witty, discusses the benefit to shareholders from his company's acquisition of Novartis' vaccination business, as well as its oncology unit.

  • GlaxoSmithKline CEO Sir Andrew Witty, explains the large portfolio of vaccinations his company provides, and the value added from the company's acquisition of Novartis' vaccination business.

  • Sarepta Therapeutics CEO Chris Garabedian discusses the prospects for what he calls a "potential accelerated approval" for its Duchenne muscular dystrophy drug Eteplirsen.

  • Sarepta muscle drug faces challenges     Monday, 21 Apr 2014 | 2:04 PM ET

    Sarepta Therapeutics is developing a drug for Duchenne muscular dystrophy. Its CEO Chris Garabedian discusses challenges the drug Eteplirsen has faced before the FDA.

  • April 14- U.S. drugstore chain operator Walgreen Co is under pressure from a group of shareholders to consider relocating to Europe to gain tax benefits, the Financial Times reported.

  • April 14- U.S. drugstore chain operator Walgreen Co is under pressure from a group of shareholders to consider relocating to Europe to gain tax benefits, the Financial Times reported.

  • Walgreens urged to leave US to gain tax benefit Monday, 14 Apr 2014 | 8:40 AM ET

    Walgreens has come under pressure from an influential group of its shareholders, who want the US pharmacy chain to consider relocating to Europe, in what would be one of the largest tax inversions ever attempted. The FT reports.

  • Hep C breakthrough     Thursday, 10 Apr 2014 | 2:53 PM ET

    CNBC contributor Barbara Ryan provides insight into new guidelines from the World Health Organization, which strongly endorses two new hepatitis c drugs.

  • April 10- Rite Aid Corp, the third-largest U.S. drugstore operator, forecast fiscal 2015 sales above analysts' estimates as it benefits from the launch of new generic drugs and enrolls more customers in its loyalty programs.

  • Flu drug stockpiles a waste of money: Report Thursday, 10 Apr 2014 | 6:27 AM ET

    The U.K. and U.S. governments spent millions stockpiling a flu drug that is no better than paracetamol, according to a new report.

  • Ultragenyx is now up around 150 percent from its IPO price. Its CEO Dr. Emil Kakkis provides insight on the development of its drugs, and just how committed the company is to treating patients with the diseases its drugs treat.

  • FTI Consulting managing director Barbara Ryan provides insight on new drugs showing dramatic improvement in the standard of care for high cholesterol.